Caplyta’s most recent FDA approval is based on positive results from two Phase III clinical trials: Study 501 (NCT04985942) and Study 502 (NCT05061706). Both studies met their primary endpoint and key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback